Seven presentations will be shared, including new data on the risks of long-term cardiovascular, renal and infection complications, underlining Takeda’s commitment to further understanding of this rare disease

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will feature 7 presentations, including one oral presentation, at the upcoming European Congress of Endocrinology (ECE) Annual Meeting from May 18-21, 2019 in Lyon, France. The data presentations include findings from new research into the long-term risks of cardiovascular, renal and infection complications that patients with chronic hypoparathyroidism may experience as well as the latest findings from on-going real world and clinical studies, including the Global Burden of Illness Survey and the 6-year RACE study.

Takeda will also sponsor two satellite symposia. The first will focus on the burden of illness in chronic hypoparathyroidism patients with impaired biochemical control and comorbidities associated with the disease (Forum 1 on May 19, 13.45–14.45). The second symposium will present new perspectives in managing not adequately controlled hypoparathyroidism patients (Forum 3 on May 20, 13.45–14.35). Takeda will also have an exhibition booth throughout the congress (Booth #B02).

“The new research we are presenting at ECE 2019 continues to further our understanding of chronic hypoparathyroidism, especially about how long-term complications and symptoms may impact patients living with this rare disease,” explained John Germak M.D., Global Medical Team Lead at Takeda. “The clinical and real-world studies reflect our commitment to advancing our knowledge of chronic hypoparathyroidism and to improving patient care,” he added.

Hypoparathyroidism is a rare endocrine disease that occurs when inadequate levels of parathyroid hormone (PTH) are secreted by the parathyroid glands, resulting in a mineral imbalance in the body expressed by a low concentration of calcium (hypocalcemia) and a high concentration of phosphate (hyperphosphatemia) in the blood. Studies have shown that a range of approximately 24–37 in 100,000 patients are affected by hypoparathyroidism. In patients who are not adequately controlled, this disease can have a significant impact on patient well-being through a range of physical, cognitive and emotional symptoms, and comorbidities.

Takeda’s presence at this year’s ECE meeting includes the following presentations, which are intended for scientific discussion only:

• Risk of sepsis, respiratory infections, and kidney or other genitourinary (GU) infections in patients with chronic hypoparathyroidism (HypoPT) OC1.4, May 19, 2019, Salle Gratte-Ciel 1+2+3, 12.00 – 13.00
• Risk of myocardial infarction, stroke and other cardiovascular conditions in patients with chronic hypoparathyroidism: A retrospective cohort GP148, May 20, 2019, Exhibition area, 13.00 – 14.00
• Risk of chronic kidney disease (CKD) and CKD progression in patients with chronic hypoparathyroidism (HypoPT) GP149, May 20, 2019, Exhibition area, 13.00 – 14.00
• Risk of nephrolithiasis and nephrocalcinosis in patients with chronic hypoparathyroidism (HypoPT) GP147, May 20, 2019, Exhibition area, 13.00 – 14.00
• Impact of chronic hypoparathyroidism on Health-Related Quality of Life: Findings from a 13-country patient survey GP25, May 19, 2019, Exhibition area, 13.00 – 14.00
• Risk of Type 2 diabetes (T2D) in patients with chronic hypoparathyroidism. (HypoPT) P1038, May 21, 2019, Exhibition area, 12.30 – 14.30
• Recombinant human parathyroid hormone 1-84 for the treatment of adults with chronic hypoparathyroidism: Six-year safety and efficacy results of the RACE study GP15, May 19, 2019, Exhibition area, 13.00 – 14.00

All abstracts will be available on the ECE website following the meeting.

Share This Post